提醒

提醒專業圖表

Personalis Inc. (PSNL)

NasdaqGM: PSNL · 即時價格 · USD

14.04

-0.38 (-2.64%)

收盤時： Aug 14, 2026, 3:59 PM

13.92

-0.86%

盤後: 7:34 PM

-2.64% (1D)

買價	9.7
市值	1.5B
營收 (ttm)	69.67M
淨利（ttm）	-107.18M
貝塔	2.29
EPS (ttm)	-1.09
本益比（ttm）	n/a
正向 PE	-14.91
P/B (ttm)	6.35
P/S (ttm)	21.51
Earnings Date	Nov 3, 2026

賣價	17.35
成交量	1,038,769
20 日平均成交量	3,876,056
打開	14.11
上一頁關閉	14.42
日間範圍	13.92 - 14.29
52 週範圍	4.44 - 16.39
分析師	Buy
目標價	14.62 (4.13%)
股利	n/a
Ex-股利日期	n/a

關於PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics t...

[閱讀更多]

工業 Diagnostics & Research

部門 Healthcare

IPO 日期 Jun 20, 2019

員工 259

證券交易所 NasdaqGM

股票代號 PSNL

網站 https://www.personalis.com

完整的公司簡介

財務表現

Personalis 在 2025 年的營收為 69.65M，較前一年的 84.61M 減少 -17.69%。淨利為 -81.27M，較前期減少 -0.02%。

財務報表

分析師預測

根據4 分析師評等，PSNL股票的平均評等為「Buy」。 12個月股價預測為14.62，與最新價格相比為上漲空間的4.13%。

股票預測

獲利驚喜

Personalis 已於 Aug 4, 2026 公布季度財報：

營收的 $22.36M 錯過估計 $0, 與 29.96% YoY 成長.

EPS 的 -0.3 錯過估計 -0.02, 與 -30.43% YoY 下降.

下次財報發布

Personalis Inc. 定於發布財報 Nov 3, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

4 天前 · Zacks

Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside

TEM raises its 2026 revenue outlook as oncology testing, data demand and FDA-linked pricing gains support growth and cash flow improvement.

1 週前 · Zacks

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 週前 · Simply Wall St.

How Investors May Respond To Tempus AI (TEM) Q2 Profit Return, Outlook Hike, Personalis Deal

In the past week, Tempus AI, Inc. reported second-quarter 2026 results showing revenue of US$382.49 million and a swing from a net loss of US$42.84 million a year ago to net income of US$5.64 million,...

2 週前 · MarketBeat

Tempus AI Q2 Earnings Call Highlights

Tempus AI (NASDAQ:TEM) reported second-quarter revenue growth of 22% and raised its full-year outlook, citing accelerating oncology testing volumes, expanding demand for its data and artificial intell...

3 週前 · TheStreet

Tempus makes $1.5B bet to corner cancer-test market

Tempus AI (TEM) spent three years selling someone else's cancer test. On Monday, July 20, it decided to just buy the whole thing. The AI diagnostics company agreed to acquire Personalis (PSNL) in a de...

第 1 頁，共 2 頁

Personalis Inc. (PSNL)